Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246 · see citing works

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116 · see citing works

Drug Transport across the Blood–Brain Barrier

Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994 · see citing works

Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850 · see citing works

Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer

Sequist, L. V., Soria, J.-C., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., Papadimitrakopoulou, V., Solomon, B. J., Oxnard, G. R., Dziadziuszko, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413654 · Cited by 665 · see citing works

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

Finlay, M. R. V., Anderton, M., Ashton, S., Ballard, P., Bethel, P. A., Box, M. R., Bradbury, R. H., Brown, S. J., Butterworth, S., Campbell, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500973a · Cited by 636 · see citing works

Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers

Rangachari, D., Yamaguchi, N., VanderLaan, P. A., Folch, E. E., Mahadevan, A., Floyd, S., Uhlmann, E. J., Wong, E. T., Dahlberg, S. E., Huberman, M. S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.020 · Cited by 539 · see citing works

The seed and soil hypothesis: vascularisation and brain metastases

Fidler, I. J., Yano, S., Zhang, R.-D., Fujimaki, T., & Bucana, C. D. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00622-2 · Cited by 432 · see citing works

“Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer

Grommes, C., Oxnard, G. R., Kris, M. G., Miller, V. A., Pao, W., Holodny, A. I., Clarke, J. L., & Lassman, A. B. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor121 · Cited by 349 · see citing works

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation

Park, S. J., Kim, H. T., Lee, D., Kim, K. P., Kim, S.-W., Suh, C. H., & Lee, J. S. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.05.092 · Cited by 323 · see citing works

Relationship Between Neurocognitive Function and Quality of Life After Whole-Brain Radiotherapy in Patients With Brain Metastasis

Li, J., Bentzen, S. M., Li, J., Renschler, M. F., & Mehta, M. P. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.09.059 · Cited by 287 · see citing works

Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer

Togashi, Y., Masago, K., Masuda, S., Mizuno, T., Fukudo, M., Ikemi, Y., Sakamori, Y., Nagai, H., Kim, Y. H., Katsura, T., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1929-4 · Cited by 282 · see citing works

Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma

Iuchi, T., Shingyoji, M., Sakaida, T., Hatano, K., Nagano, O., Itakura, M., Kageyama, H., Yokoi, S., Hasegawa, Y., Kawasaki, K., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.016 · Cited by 257 · see citing works

Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease

Hoffknecht, P., Tufman, A., Wehler, T., Pelzer, T., Wiewrodt, R. G., Schütz, M., Serke, M. H., Stöhlmacher-Williams, J., Märten, A., Huber, R. M., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000380 · Cited by 255 · see citing works

Clinical Predictors of Metastatic Disease to the Brain from Non–Small Cell Lung Carcinoma: Primary Tumor Size, Cell Type, and Lymph Node Metastases

Mujoomdar, A., Austin, J. H. M., Malhotra, R., Powell, C. A., Pearson, G. D. N., Shiau, M. C., & Raftopoulos, H. (2007) · Radiology · doi:10.1148/radiol.2423051707 · Cited by 229 · see citing works

High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib

Omuro, A. M. P., Kris, M. G., Miller, V. A., Franceschi, E., Shah, N. T., Milton, D. T., & Abrey, L. E. (2005) · Cancer · doi:10.1002/cncr.21033 · Cited by 227 · see citing works

Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson’s disease

Jučaitė, A., Svenningsson, P., Rinne, J. O., Cselényi, Z., Varnäs, K., Johnström, P., Amini, N., Kirjavainen, A. K., Helin, S., Minkwitz, M. C., et al. (2015) · Brain · doi:10.1093/brain/awv184 · Cited by 224 · see citing works

Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib

Héon, S., Yeap, B. Y., Britt, G. J., Costa, D. B., Rabin, M. S., Jackman, D. M., & Johnson, B. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1588 · Cited by 216 · see citing works

Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT

Varrone, A., Sjöholm, N., Eriksson, L., Gulyás, B. Z., Halldin, C., & Farde, L. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1156-3 · Cited by 204 · see citing works

The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with <i>EGFR</i> Mutations

Heon, S., Yeap, B. Y., Lindeman, N. I., Joshi, V. A., Butaney, M., Britt, G. J., Costa, D. B., Rabin, M. S., Jackman, D. M., & Johnson, B. E. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0357 · Cited by 176 · see citing works

Leptomeningeal metastasis: survival and prognostic factors in 155 patients

Herrlinger, U., Förschler, H., Küker, W., et al. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.05.008 · Cited by 175 · see citing works

Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP

de Vries, N. A., Buckle, T., Zhao, J., Beijnen, J. H., Schellens, J. H. M., & van Tellingen, O. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9569-1 · Cited by 161 · see citing works

Positron Emission Tomography (PET) Imaging with [11C]-Labeled Erlotinib: A Micro-PET Study on Mice with Lung Tumor Xenografts

Memon, A. A., Jakobsen, S., Dagnæs‐Hansen, F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3118 · Cited by 156 · see citing works

Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases

Zimmermann, S., Dziadziuszko, R., & Peters, S. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.03.005 · Cited by 147 · see citing works

Monoclonal antibodies in neuro-oncology

Lampson, L. A. (2011) · mAbs · doi:10.4161/mabs.3.2.14239 · Cited by 144 · see citing works

Whole brain radiotherapy for brain metastasis

Chinnaiyan, P., McTyre, E., & Scott, J. G. (2013) · Surgical Neurology International · doi:10.4103/2152-7806.111301 · Cited by 138 · see citing works

Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man.

McKillop, D., Hutchison, M., Partridge, E. A., Bushby, N., Cooper, C. M. F., Clarkson-Jones, J. A., Herron, W., & Swaisland, H. C. (2004) · Xenobiotica · doi:10.1080/00498250400009171 · Cited by 130 · see citing works

Brain metastases

Wen, P. Y., & Loeffler, J. S. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0072-3 · Cited by 129 · see citing works

Site-specific metastasis of mouse melanomas and a fibrosarcoma in the brain or meninges of syngeneic animals.

Schackert, G., & Fidler, I. J. (1988) · PubMed · Cited by 117 · see citing works

Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation

Elmeliegy, M. A., Carcaboso, A. M., Tagen, M., Bai, F., & Stewart, C. F. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1934 · Cited by 109 · see citing works

Brain metastases

Norden, A. D., Wen, P. Y., & Kesari, S. (2005) · Current Opinion in Neurology · doi:10.1097/01.wco.0000191514.37498.2b · Cited by 102 · see citing works

Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic–Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104

Yates, J. W. T., Ashton, S. E., Cross, D. A. E., Mellor, M. J., Powell, S. J., & Ballard, P. G. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0142 · Cited by 52 · see citing works

Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies

Kemper, E. M., Leenders, W. P. J., Küsters, B., Lyons, S. K., Buckle, T., Heerschap, A., Boogerd, W. J., Beijnen, J. H., & van Tellingen, O. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.07.013 · Cited by 51 · see citing works

Exploring In Silico Prediction of the Unbound Brain-to-Plasma Drug Concentration Ratio: Model Validation, Renewal, and Interpretation

Varadharajan, S., Winiwarter, S., Carlsson, L., et al. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24301 · Cited by 48 · see citing works

Large Variation in Brain Exposure of Reference CNS Drugs: a PET Study in Nonhuman Primates

Schou, M., Varnäs, K., Lundquist, S., Nakao, R., Amini, N., Takano, A., Finnema, S. J., Halldin, C., & Farde, L. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv036 · Cited by 45 · see citing works

Making the Brain Glow: In Vivo Bioluminescence Imaging to Study Neurodegeneration

Hochgräfe, K., & Mandelkow, E. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8379-1 · Cited by 41 · see citing works

Role of breast cancer resistance protein (BCRP) as active efflux transporter on blood-brain barrier (BBB) permeability

Garg, P., Dhakne, R., & Belekar, V. (2014) · Molecular Diversity · doi:10.1007/s11030-014-9562-2 · Cited by 37 · see citing works

EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer

Bartolotti, M., Franceschi, E., & Brandes, A. A. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.121 · Cited by 36 · see citing works

AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): preclinical evidence and clinical cases

Kim, D.-W., Yang, J. C.-H., Chen, K., Cheng, Z., Yin, L., Martin, P. D., Yang, Z., Jiang, H., & Ahn, M.-J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8016 · Cited by 33 · cited 1× · see citing works

Arrest and Retention of Multilamellar Liposomes in the Brain of Normal Mice or Mice Bearing Experimental Brain Metastases

Schackert, G., Fan, D., Nayar, R., et al. (1989) · Selective Cancer Therapeutics · doi:10.1089/sct.1989.5.73 · Cited by 28 · see citing works

Development of rapid multistep carbon-11 radiosynthesis of the myeloperoxidase inhibitor AZD3241 to assess brain exposure by PET microdosing

Johnström, P., Bergman, L. B., Varnäs, K., et al. (2015) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2015.02.001 · Cited by 26 · see citing works

In Silico Prediction of Inhibition of Promiscuous Breast Cancer Resistance Protein (BCRP/ABCG2)

Ding, Y.-L., Shih, Y.-H., Tsai, F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090689 · Cited by 21 · see citing works

Preliminary Azd9291 Western and Asian Clinical Pharmacokinetics (Pk) in Patients (Pts) and Healthy Volunteers (Hv): Implications for Formulation, Dose and Dosing Frequency in Pivotal Clinical Studies

Planchard, D., Dickinson, P. A., Brown, K. H., Kim, D. S., Kim, S., Ohe, Y., Felip, E., Leese, P. T., Cantarini, M., & Ranson, M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu331.24 · Cited by 3 · see citing works

Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer

Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508 · see citing works

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379 · see citing works

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Han, J.-Y., Katakami, N., Kim, H. R., Hodge, R., Kaur, P., Brown, A. P., Ghiorghiu, D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9363 · Cited by 517 · see citing works

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

Yang, J. C. H., Kim, S.-W., Kim, D.-W., Lee, J.-S., Cho, B. C., Ahn, J.-S., Lee, D. H., Kim, T. M., Goldman, J. W., Natale, R. B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00457 · Cited by 395 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

Targeting EGFR in Lung Cancer: Current Standards and Developments

Díaz-Serrano, A., Gella, P., Jiménez, E., Zugazagoitia, J., & Paz-Ares Rodríguez, L. (2018) · Drugs · doi:10.1007/s40265-018-0916-4 · Cited by 108 · see citing works

Optimizing outcomes in <i>EGFR</i> Mutation-Positive Nsclc: Which Tyrosine Kinase Inhibitor and When?

Girard, N. (2018) · Future Oncology · doi:10.2217/fon-2017-0636 · Cited by 103 · see citing works

EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib

Jenkins, S., Chih-Hsin Yang, J., Jänne, P. A., Thress, K. S., Yu, K., Hodge, R., Weston, S., Dearden, S., Patel, S., Cantarini, M., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.05.002 · Cited by 53 · see citing works

Irreversible EGFR Inhibitors in the Treatment of Advanced NSCLC

Maione, P., Rossi, A., Bareschino, M., et al. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660764 · Cited by 10 · see citing works

Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation

Yang, X., Huang, C., Chen, R., & Zhao, J. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.12.002 · Cited by 25 · see citing works

EP1.14-10 Investigation of Mechanisms of Acquired Resistance to Afatinib with Plasma DNA in Non-Small Cell Lung Cancer Patients

Sueoka‐Aragane, N., Nakamura, T., Nakashima, C., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.2295

The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC

Tamiya, M., Tamiya, A., Okamoto, N., Taniguchi, Y., Nishino, K., Atagi, S., Hirashima, T., Imamura, F., Kumagai, T., & Suzuki, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-89006-9 · Cited by 7 · see citing works

127 INVITED Translational reseach is key in clinical trials: MD/PhDs in the driving seat …

Eggermont, A. M. M. (2007) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(07)70241-0